{"id":553295,"date":"2026-04-18T22:37:35","date_gmt":"2026-04-18T20:37:35","guid":{"rendered":"https:\/\/medizinonline.com\/?p=553295"},"modified":"2026-04-18T22:37:48","modified_gmt":"2026-04-18T20:37:48","slug":"conjugados-anticorpo-farmaco-em-oncologia-ginecologica","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/pt-pt\/conjugados-anticorpo-farmaco-em-oncologia-ginecologica\/","title":{"rendered":"Conjugados anticorpo-f\u00e1rmaco em oncologia ginecol\u00f3gica"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Os conjugados <em> anticorpo-f\u00e1rmaco <\/em>(ADC) alteraram profundamente a oncologia ginecol\u00f3gica num espa\u00e7o de tempo muito curto. Em apenas dois anos, tr\u00eas ADC &#8211; mirvetuximab soravtansine, tisotumab vedotin e trastuzumab deruxtecan &#8211; foram aprovados para tumores ginecol\u00f3gicos do ov\u00e1rio, do colo do \u00fatero e todos os tumores s\u00f3lidos HER2-positivos, incluindo o cancro do endom\u00e9trio e do ov\u00e1rio. A an\u00e1lise final de sobreviv\u00eancia do ensaio MIRASOL (SGO 2025) e a aprova\u00e7\u00e3o total do tisotumab vedotin (abril de 2024) consolidam a posi\u00e7\u00e3o desta classe de subst\u00e2ncias.  <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/pt-pt\/a-minha-conta\/pacotes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/pt-pt\/iniciar-sessao\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fpt-pt%2Fconjugados-anticorpo-farmaco-em-oncologia-ginecologica%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Os conjugados anticorpo-f\u00e1rmaco (ADC) alteraram profundamente a oncologia ginecol\u00f3gica num espa\u00e7o de tempo muito curto. Em apenas dois anos, tr\u00eas ADC &#8211; mirvetuximab soravtansine, tisotumab vedotin e trastuzumab deruxtecan &#8211;&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/pt-pt\/a-minha-conta\/pacotes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/pt-pt\/iniciar-sessao\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fpt-pt%2Fconjugados-anticorpo-farmaco-em-oncologia-ginecologica%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":553296,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Novas aprova\u00e7\u00f5es, dados de estudos actuais e desenvolvimento de ADC  ","footnotes":""},"category":[11551,11521,11524,11419,11379],"tags":[90861,15148,18153,90859,90860],"powerkit_post_featured":[],"class_list":["post-553295","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-pt","category-estudos","category-formacao-continua","category-ginecologia-pt-pt","category-oncologia-pt-pt","tag-anticorpos-onoclonais","tag-carcinoma-do-colo-do-utero","tag-carcinoma-ovariano","tag-conjugado-anticorpo-farmaco","tag-terapia-adc","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-12 04:31:46","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"pt_PT","wpml_translations":{"es_ES":{"locale":"es_ES","id":553292,"slug":"conjugados-anticuerpo-farmaco-en-oncologia-ginecologica","post_title":"Conjugados anticuerpo-f\u00e1rmaco en oncolog\u00eda ginecol\u00f3gica","href":"https:\/\/medizinonline.com\/es\/conjugados-anticuerpo-farmaco-en-oncologia-ginecologica\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/553295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=553295"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/553295\/revisions"}],"predecessor-version":[{"id":553297,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/553295\/revisions\/553297"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/media\/553296"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=553295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/category?post=553295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/tags?post=553295"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/powerkit_post_featured?post=553295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}